Literature DB >> 22010009

Treatment of locally recurrent mucosal melanoma with topical imiquimod.

Elizabeth C Smyth1, Marisa Flavin, Melissa P Pulitzer, Ginger J Gardner, Peter D Costantino, Dennis S Chi, Kita Bogatch, Paul B Chapman, Jedd D Wolchok, Gary K Schwartz, Richard D Carvajal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22010009     DOI： 10.1200/JCO.2011.36.8829

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Plasmacytoid dendritic cells lead the charge against tumors.

Authors:  Sonia Jiménez-Baranda; Inês Pires Silva; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

Review 2.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

3.  Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature.

Authors:  Emmanouil Kalampokas; Theodoros Kalampokas; Christos Damaskos
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

4.  Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.

Authors:  Sanxiong Xu; Zuozhang Yang; Jinyu Zhang; Yongxin Jiang; Yongbin Chen; Hongjun Li; Xuefeng Liu; Da Xu; Yanjin Chen; Yihao Yang; Ya Zhang; Dongxu Li; Junfeng Xia
Journal:  DNA Cell Biol       Date:  2015-01       Impact factor: 3.311

5.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Authors:  Matthew J Frank; Patrick M Reagan; Nancy L Bartlett; Leo I Gordon; Jonathan W Friedberg; Debra K Czerwinski; Steven R Long; Richard T Hoppe; Robert Janssen; Albert F Candia; Robert L Coffman; Ronald Levy
Journal:  Cancer Discov       Date:  2018-08-28       Impact factor: 39.397

Review 6.  Evolving Treatment Approaches to Mucosal Melanoma.

Authors:  Shuai Zhang; Jiaran Zhang; Jun Guo; Lu Si; Xue Bai
Journal:  Curr Oncol Rep       Date:  2022-05-05       Impact factor: 5.945

7.  Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.

Authors:  M Zahidunnabi Dewan; Claire Vanpouille-Box; Noriko Kawashima; Sara DiNapoli; James S Babb; Silvia C Formenti; Sylvia Adams; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-10-09       Impact factor: 12.531

Review 8.  In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Authors:  Linda Hammerich; Adam Binder; Joshua D Brody
Journal:  Mol Oncol       Date:  2015-11-10       Impact factor: 6.603

Review 9.  The Yin and Yang of Toll-like receptors in cancer.

Authors:  J-P Pradere; D H Dapito; R F Schwabe
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

10.  Topical treatment of recurrent vaginal melanoma in situ with imiquimod: A case report.

Authors:  Lauren S Prescott; Nicholas E Papadopoulos; Elizabeth D Euscher; Jack L Watkins; Kathleen M Schmeler
Journal:  Gynecol Oncol Case Rep       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.